Immunotherapy in Oncology Patent Landscape Report 2024

Patent Landscape Report Coverage

The immunotherapy in oncology patent landscape report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for immunotherapy in oncology include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within immunotherapy in oncology technologies.

As of May 2017, 1300+ patent families existed that recited both CTL A-4 and antibody in their claims. Moreover, approximately 500 patent families are directed to antibodies against the PD-1/PD-L1 interaction, 100 patent families are directed to antibodies and TIM3 or LAG 3, while around 300 patent families are directed to antibodies and OX40. The patent claim language is crucial for the protection of inventions, and thus the patent filings are witnessing a surge, impacting the landscape significantly.

Immunotherapy in Oncology Patent Market Outlook

• The competitive dynamics within oncology immunotherapy are competitive. Many companies are protecting their innovations related to immune checkpoint inhibitors, cancer vaccines, CAR-T cell therapies, and other immunotherapeutic treatments. Major pharma companies like Bristol Myers Squibb and Merck have already established strong patent portfolios in cancer immunotherapy.

• The advancements in treatment technology, such as personalized medicine and CRISPR-Cas9 gene editing impact the patent landscape in oncology immunotherapy. These potential technologies are leading to new development of patentable innovations.

• Major companies and research institutions are adopting strategic initiatives to build strong patent portfolios. The strategy includes filing patent applications early in the process of development to secure priority rights, engaging in patent licensing, and conducting comprehensive patent searches to avoid any infringement. In 2022, there was a notable rise in patent filing applications which reached a value of more than 3800 patent filing applications, signifying the treatment efficiency of immunotherapy.

What is Oncology Immunotherapy?

Immunotherapy is a specialized treatment in which a person’s own immune system is used to fight cancer cells. This treatment can boost how the immune system attacks the cancer cells. This can be done in several ways, including stimulating the natural defenses of the immune system to attack cancer cells or by making substances in a lab, like immune system components and using that to restore the working of the immune system to attack cancer cells. There are multiple types of immunotherapies including checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, immunomodulators, cancer vaccines, and monoclonal antibodies.

The first commercial development of therapeutic monoclonal antibodies began in the 1980s. Since then, monoclonal antibodies have emerged as one of the major drug classes in the field of biopharmaceuticals.

Immunotherapy in Oncology Industry Growth Drivers

Successful Clinical Trials for Immune Checkpoint Inhibitors and CAR T-Cell Therapies is Expected to Augment the Patent Industry Growth

The successful development in the immunotherapy treatments, such as immune checkpoint inhibitors and CAR-T cell therapies has fueled the investment in this field. The positive clinical trial results reflecting improved and efficient treatment outcomes are driving the demand for protection of patents to secure market exclusivity.

The noticeable advancement in cancer immunotherapy is the FDA approval of checkpoint inhibitors including PD-1/PD-L1 inhibitors such as Nivolumab, Pembrolizumab, Avelumab, and Atezolizumab. These therapies have significantly improved the treatment outcomes of renal cancer, bladder cancer, on-small cell lung cancer (NSCLC), head and neck cancer and melanoma. Therefore, it is essential to develop strong patent portfolios to protect such innovative therapies.

Shifting Trend towards Combination Therapies is Expected to Propel Immunotherapy in Oncology Patent Industry Growth

There is an ongoing trend towards combining more than one immunotherapy with other treatment options including such as chemotherapy or radiation therapy. This combined approach is driving innovation and an increase in patent filings.

The monoclonal antibodies along with other antibody-related products including antibody fragments, and antibody-drug conjugates, have emerged as a major drug class. This combinatory treatment has proven effective for cancer treatment. Companies are filing patents to protect novel combination therapies, thereby impacting the patent landscape significantly.

Immunotherapy in Oncology Patent Segmentation

The report will cover the following sections in detail:

Breakup by Type

• Monoclonal Antibodies (mAbs)

• CAR-T Cell

• Immune Checkpoint Inhibitor/Modulator

• Bispecific Antibody

• Vaccine

• Others

Breakup by Indication

• Lung Cancer

• Colorectal Cancer

• Melanoma

• Breast Cancer

• Prostate Cancer

• Others

Immunotherapy in Oncology Patent Segmentation Analysis

The breakup based on type, includes monoclonal antibodies, cytokines and immunomodulators, checkpoint inhibitors, and others.

For instance, T-cell therapy is a successful treatment in the biopharmaceutical industry. This therapy involves reprogramming a patient’s own immune T cells to attack tumors. A type of T-cell therapy comprises the adoptive transfer of chimeric antigen receptor (CAR) T-cells. The benefit of CAR T-cells include that such cells can be engineered to target any tumor-associated antigen.

The detailed technological data will be provided for all specified segments classified in this report.

Immunotherapy in Oncology Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for oncology immunotherapy patents, having around 34,000 patents. The presence of major pharmaceutical companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the patent landscape significantly.

Patent Profile of Key Companies

Among the players in oncology immunotherapy patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Bristol Myers Squibb Co

Bristol Myers Squibb, founded in 1887 and headquartered in the United States is a global pharmaceutical company engaged in the development of multiple therapeutic areas including cancer, cardiovascular diseases, hepatitis, diabetes, and psychiatric disorders among others. The company developed Ipilimumab, a drug that targets CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4) and continues to research and develop in the field of immunotherapy.

Novartis AG

Novartis AG, founded in 1996 and headquartered at Switzerland, is a global pharmaceutical company, engaged in ...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other companies include Genentech Inc., AstraZeneca, Immatics Biotechnologies Gmbh, F. Hoffmann La Roche, Incyte Corp, and others.

Reasons to Purchase this Report

The immunotherapy in oncology patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by -

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators also makes it understandable which companies have important patents in this field of immunotherapy in oncology.

• Innovation Insights: The patent analysis reveals new innovations and technologies in immunotherapy in oncology industry.

• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry.

• Risk Assessment: In technology-intensive fields such as immunotherapy in oncology, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Immunotherapy in Oncology Patent Landscape Report

• Who are the key players in the immunotherapy in oncology patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in immunotherapy in oncology patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in immunotherapy in the oncology industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in immunotherapy in oncology?
• What are the challenges and opportunities in the immunotherapy in oncology patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in immunotherapy in oncology?

Related Reports

Global Cancer Immunotherapy Market 

Global Immunotherapy Drugs Market

Global Monoclonal Antibodies Market

Global Cancer Vaccines Market